Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
- 1 May 1994
- journal article
- Published by Elsevier in Metabolism
- Vol. 43 (5) , 647-654
- https://doi.org/10.1016/0026-0495(94)90209-7
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive menJournal of Clinical Endocrinology & Metabolism, 1993
- Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. In vivo and in vitro studies of hyperandrogenic femalesDiabetes, 1991
- Sensitivity of pyruvate dehydrogenase to insulin in activated T lymphocytes. Lack of responsiveness to insulin in patients with polycystic ovarian disease and diabetesDiabetes, 1990
- POLYCYSTIC OVARY SYNDROME: A CHANGING PERSPECTIVEClinical Endocrinology, 1989
- HETEROGENEITY OF THE POLYCYSTIC OVARY SYNDROME: CLINICAL, ENDOCRINE AND ULTRASOUND FEATURES IN 556 PATIENTSClinical Endocrinology, 1989
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988
- Insulin Resistance in Essential HypertensionNew England Journal of Medicine, 1987
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Hyperinsulinemia in a Population at High Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1986
- Plasma Insulin as Coronary Heart Disease Risk Factor: Relationship to other Risk Factors and Predictive Value during 9½‐year Follow‐up of the Helsinki Policemen Study PopulationActa Medica Scandinavica, 1985